[Galcanezumab for episodic and chronic cluster headache]

Area of Science:

• Neurology
• Pharmacology
• Headache Medicine

Context:

• Cluster headache (CH) is a severe neurological disorder causing debilitating unilateral pain and autonomic symptoms.
• Calcitonin gene-related peptide (CGRP) plays a crucial role in the pathophysiology of cluster headaches.
• Developing effective preventive treatments for CH remains a significant clinical challenge.

Purpose:

• To evaluate the preventive efficacy and tolerability of galcanezumab, an anti-CGRP antibody, in patients with episodic cluster headache (eCH) and chronic cluster headache (cCH).
• To review study findings and discuss challenges in developing preventive therapies for CH.

Summary:

• Phase III trials assessed galcanezumab (300 mg subcutaneously every 4 weeks) against placebo in eCH and cCH patients.
• In eCH, galcanezumab significantly reduced weekly attack frequency by 52% compared to placebo (27%, p=0.036).
• The primary endpoint was not met in cCH, with galcanezumab showing a mean weekly attack rate reduction of 5.4 versus 4.6 for placebo (p=0.334); galcanezumab was well-tolerated in both groups.

Impact:

• Galcanezumab demonstrates significant potential as a preventive treatment for episodic cluster headaches.
• The lack of efficacy in chronic cluster headaches highlights the need for further research into CH subtypes and treatment strategies.
• This study contributes to understanding CGRP's role and informs future drug development for debilitating headache disorders.